up-to-date with a click!
Update July, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications July 2018

Add on treatments

  1. van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular diabetology 2018; 17:94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960584
  2. Lu YW, Zhu YC, Zhang L et al. Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics. Chinese journal of natural medicines 2018; 16:436-445. http://www.ncbi.nlm.nih.gov/pubmed/?term=30047465
  3. Marzal D, Rodriguez Padial L, Arnaiz JA et al. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention. Clin Investig Arterioscler 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30017176
  4. Cofan M, Ros E. Use of plant sterol and stanol fortified foods in clinical practice. Curr Med Chem 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984649
  5. Danielak D, Karazniewicz-Lada M, Glowka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30003466
  6. Ezetimibe. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  7. Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs in context 2018; 7:212534. http://www.ncbi.nlm.nih.gov/pubmed/?term=30023003
  8. Bougarne N, Weyers B, Desmet SJ et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocrine reviews 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30020428
  9. Janssen VE, Visseren FL, de Boer A et al. Combined use of polypill components in patients with type 2 diabetes mellitus. Eur J Prev Cardiol 2018:2047487318789494. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033753
  10. Fan Y, Jin X, Man C, Gong D. Does Adjuvant Treatment With Ginkgo Biloba to Statins Have Additional Benefits in Patients With Dyslipidemia? Frontiers in pharmacology 2018; 9:659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29988404
  11. Seyam E, Hefzy E. Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30044162
  12. Ibanez B, Castellano JM, Fuster V. Polypill strategy at the heart of cardiovascular secondary prevention. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30030331
  13. Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of medication errors. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30072364
  14. Fukumoto Y. Impact of statin-ezetimibe combination in chronic kidney disease. Int J Cardiol 2018; 268:36-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30041796
  15. Dagenais GR, Jung H, Lonn E et al. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033433
  16. Choo EH, Han EJ, Kim CJ et al. Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT. Korean Circ J 2018; 48:591-601. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968431
  17. Lee JY, Cha BS. Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation. Korean Circ J 2018; 48:602-604. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968432
  18. Akbari H, Asadikaram G, Jafari A et al. Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29981321
  19. Zhang J, Liu N, Yang C. Effects of Rosuvastatin in combination with Nimodipine in patients with mild cognitive impairment caused by CSVD. Panminerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962180
  20. Ma YR, Wu YF, Duan YQ et al. [Effects of metoprolol or/and pravastatin on the pharmacokinetics of metformin in rats]. Yao xue xue bao = Acta pharmaceutica Sinica 2017; 52:253-257. http://www.ncbi.nlm.nih.gov/pubmed/?term=29979507

Adherence

  1. Ofori-Asenso R, Ilomaki J, Tacey M et al. Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. American journal of Alzheimer's disease and other dementias 2018:1533317518787314. http://www.ncbi.nlm.nih.gov/pubmed/?term=29991271
  2. Mefford MT, Tajeu GS, Tanner RM et al. Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30057227
  3. Ozkan B, Orscelik O, Uyar H et al. Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease. BioMed research international 2018; 2018:8961690. http://www.ncbi.nlm.nih.gov/pubmed/?term=29977920
  4. von Buedingen F, Hammer MS, Meid AD et al. Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. BMC family practice 2018; 19:131. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055583
  5. Kaltoft MK, Nielsen JB, Dowie J. Risk Thresholds and Risk Classifications Pose Problems for Person-Centred Care. Studies in health technology and informatics 2018; 251:19-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968591

Atherosclerosis & Imaging

  1. Tokuhisa H, Murai H, Okabe Y et al. Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction. Autonomic neuroscience : basic & clinical 2018; 213:8-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30005743
  2. Kim CJ, Han EJ, Chu EH et al. Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery. Cardiology journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30009378
  3. Kerut EK, Hall ME, Turner MC, McMullan MR. Coronary risk assessment using traditional risk factors with CT coronary artery calcium scoring in clinical practice. Echocardiography (Mount Kisco, N.Y.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29974506
  4. Lind PM, Salihovic S, Stubleski J et al. Changes in plasma levels of perfluoroalkyl substances (PFASs) are related to increase in carotid intima-media thickness over 10 years - a longitudinal study. Environmental health : a global access science source 2018; 17:59. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970113
  5. Asleh R, Briasoulis A, Pereira NL et al. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC heart failure 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30019530
  6. Lim JW, Jeong HS, Hong SJ et al. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30047013
  7. Yamamoto H, Kihara Y, Kitagawa T et al. Coronary plaque characteristics in computed tomography and 2-year outcomes: The PREDICT study. Journal of cardiovascular computed tomography 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30017608
  8. Ye H, Wang S, Hu Y et al. Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography. Medicine (Baltimore) 2018; 97:e11718. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075578
  9. Li H, Chen C, Wang D. Lowfrequency ultrasound and microbubbles combined with simvastatin promote the apoptosis of MCF7 cells by affecting the LATS1/YAP/RHAMM pathway. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015955
  10. Ozaki Y, Tanaka A, Nishiguchi T et al. High-density lipoprotein cholesterol as a therapeutic target for residual risk in patients with acute coronary syndrome. PLoS One 2018; 13:e0200383. http://www.ncbi.nlm.nih.gov/pubmed/?term=29995934

Atorvastatin/Rosuvastatin

  1. Li J, Feng X, Shi J et al. Porous Polylactide Film Plus Atorvastatin-Loaded Thermogel as an Efficient Device for Peritoneal Adhesion Prevention. ACS omega 2018; 3:2715-2723. http://www.ncbi.nlm.nih.gov/pubmed/?term=30023849
  2. Nikolic Turnic TR, Jakovljevic VP, Djuric D et al. Efficency of Atorvastatin and Simvastatin in Improving of Cardiac Function during the Different Degree of Hyperhomocysteinemia. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30067069
  3. Tissier F, Farhat F, Philouze C et al. Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in WHHL rabbit. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30011375
  4. Dixit A, Abrudescu A. A Case of Atorvastatin-Associated Necrotizing Autoimmune Myopathy, Mimicking Idiopathic Polymyositis. Case Rep Rheumatol 2018; 2018:5931046. http://www.ncbi.nlm.nih.gov/pubmed/?term=30026996
  5. Liu ZJ, Hu GP, Fei MY et al. Effects of Short-term High Dose Atorvastatin on Left Ventricular Remodeling in Patients with First Time Attack of Anterior Acute Myocardial Infarction. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences 2018; 33:84-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29976277
  6. Marzal D, Rodriguez Padial L, Arnaiz JA et al. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention. Clin Investig Arterioscler 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30017176
  7. Ren J, Liu W, Li GC et al. Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCepsilon Pathway. Current medical science 2018; 38:405-412. http://www.ncbi.nlm.nih.gov/pubmed/?term=30074205
  8. Kong R, Zhu X, Meteleva ES et al. Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability. Drug delivery and translational research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039497
  9. Li J, Yang M, Xu W. Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. Drug design, development and therapy 2018; 12:2241-2248. http://www.ncbi.nlm.nih.gov/pubmed/?term=30050285
  10. Rosuvastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  11. Atorvastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  12. Ho K, Jamsen KM, Bell JS et al. Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027413
  13. Murtola TJ, Syvala H, Tolonen T et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. European urology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30031572
  14. Zhang T, Lu D, Yang W et al. HMG-CoA Reductase Inhibitors Relieve Endoplasmic Reticulum Stress by Autophagy Inhibition in Rats With Permanent Brain Ischemia. Frontiers in neuroscience 2018; 12:405. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970982
  15. Abd-Elsalam WH, El-Helaly SN, Ahmed MA, Al-Mahallawi AM. Preparation of novel phospholipid-based sonocomplexes for improved intestinal permeability of rosuvastatin: In vitro characterization, dynamic simulation, Caco-2 cell line permeation and in vivo assessment studies. Int J Pharm 2018; 548:375-384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29991454
  16. Hamzeh M, Hosseinimehr SJ, Mohammadi HR et al. Atorvastatin attenuates the ovarian damage induced by cyclophosphamide in rat: An experimental study. International journal of reproductive biomedicine (Yazd, Iran) 2018; 16:323-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027148
  17. Ji T, Zhao Y, Wang J et al. Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial. Journal of the American Medical Directors Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006015
  18. Turner RM, Fontana V, Bayliss M et al. Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. Journal of pharmaceutical and biomedical analysis 2018; 159:272-281. http://www.ncbi.nlm.nih.gov/pubmed/?term=30005242
  19. Jiang R, Zhao S, Wang R et al. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073290
  20. Akbari H, Asadikaram G, Jafari A et al. Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29981321
  21. Wang L, Wang Y, Wang H et al. The influence of the intestinal microflora to the efficacy of Rosuvastatin. Lipids Health Dis 2018; 17:151. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960598
  22. Ye H, Wang S, Hu Y et al. Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography. Medicine (Baltimore) 2018; 97:e11718. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075578
  23. Choi NY, Kim JY, Hwang M et al. Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen-Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways. Mol Neurobiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073508
  24. Moid M, Afzal S, Rahim N et al. High performance liquid chromatographic method validation for determination of rosuvastatin calcium in tablet dosage forms. Pak J Pharm Sci 2018; 31:1577-1582. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058551
  25. Zhang J, Liu N, Yang C. Effects of Rosuvastatin in combination with Nimodipine in patients with mild cognitive impairment caused by CSVD. Panminerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962180
  26. Alshora DH, Ibrahim MA, Elzayat E et al. Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. PLoS One 2018; 13:e0200218. http://www.ncbi.nlm.nih.gov/pubmed/?term=29985967
  27. Wybraniec MT, Filipecki A, Chudek J, Mizia-Stec K. Atorvastatin facilitates protection against contrast-induced nephropathy in patients undergoing coronary angiography via humoral mediators rather than altered renal hemodynamics. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology 2018; 14:191-194. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008773
  28. Husain I, Akhtar M, Madaan T et al. Rosuvastatin alleviates high-salt and cholesterol diet-induced cognitive impairment in rats via Nrf2-ARE pathway. Redox report : communications in free radical research 2018; 23:168-179. http://www.ncbi.nlm.nih.gov/pubmed/?term=29961403

Basic science

  1. Huang J, Lin C, Fang J et al. The pH-sensitive nanocarrier mediated codelivery of simvastatin and noggin siRNA for synergistic enhancement of osteogenesis. ACS applied materials & interfaces 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30067011
  2. Li J, Feng X, Shi J et al. Porous Polylactide Film Plus Atorvastatin-Loaded Thermogel as an Efficient Device for Peritoneal Adhesion Prevention. ACS omega 2018; 3:2715-2723. http://www.ncbi.nlm.nih.gov/pubmed/?term=30023849
  3. Araujo-Lima CF, Peres RB, Silva PB et al. Repurposing strategy of atorvastatin against Trypanosoma cruzi: in vitro monotherapy and combined therapy with benznidazole exhibits synergistic trypanocidal activity. Antimicrobial agents and chemotherapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29987140
  4. Wang C, Li T, Yan F et al. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 105:1054-1061. http://www.ncbi.nlm.nih.gov/pubmed/?term=30021341
  5. Zhou J, Gao X, Huang S et al. Simvastatin Improves the Jaw Bone Microstructural Defect Induced by High Cholesterol Diet in Rats by Regulating Autophagic Flux. BioMed research international 2018; 2018:4147932. http://www.ncbi.nlm.nih.gov/pubmed/?term=30050930
  6. Subhan M, Faryal R, Macreadie I. Statin resistance in Candida glabrata. Biotechnology letters 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30054755
  7. Tissier F, Farhat F, Philouze C et al. Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in WHHL rabbit. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30011375
  8. Veerabrahma K, Katla VM. Improvement of anti-hyperlipidemic activity and oral bioavailability of Fluvastatin via solid self-microemulsifying systems and comparative with liquisolid formulation. Current drug delivery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033871
  9. Ren J, Liu W, Li GC et al. Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCepsilon Pathway. Current medical science 2018; 38:405-412. http://www.ncbi.nlm.nih.gov/pubmed/?term=30074205
  10. Dworacka M, Iskakova S, Wesolowska A et al. Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability. Diabetes Res Clin Pract 2018; 143:245-253. http://www.ncbi.nlm.nih.gov/pubmed/?term=30056191
  11. Kong R, Zhu X, Meteleva ES et al. Atorvastatin calcium inclusion complexation with polysaccharide arabinogalactan and saponin disodium glycyrrhizate for increasing of solubility and bioavailability. Drug delivery and translational research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039497
  12. Xie Y, Liu C, Huang H et al. Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment. Drug delivery and translational research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027372
  13. Li J, Yang M, Xu W. Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. Drug design, development and therapy 2018; 12:2241-2248. http://www.ncbi.nlm.nih.gov/pubmed/?term=30050285
  14. Ruan H, Yu Y, Guo X et al. The possibility of healing alveolar bone defects with simvastatin thermosensitive gel: in vitro/in vivo evaluation. Drug design, development and therapy 2018; 12:1997-2003. http://www.ncbi.nlm.nih.gov/pubmed/?term=30013319
  15. Mathur M, Vemula KD. Investigation of different types of nano drug delivery systems of Atorvastatin for the treatment of Hyperlipidemia. Drug development and industrial pharmacy 2018:1-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073852
  16. Han Y, Kim SJ. Simvastatin-dependent actin cytoskeleton rearrangement regulates differentiation via the extracellular signal-regulated kinase-1/2 and p38 kinase pathways in rabbit articular chondrocytes. Eur J Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30009811
  17. Wang HM, Gao JH, Lu JL. Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12. Eur Rev Med Pharmacol Sci 2018; 22:4995-5003. http://www.ncbi.nlm.nih.gov/pubmed/?term=30070336
  18. Einbond LS, Soffritti M, Esposti DD et al. A transcriptomic analysis of black cohosh: Actein alters cholesterol biosynthesis pathways and synergizes with simvastatin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29969672
  19. Zhang T, Lu D, Yang W et al. HMG-CoA Reductase Inhibitors Relieve Endoplasmic Reticulum Stress by Autophagy Inhibition in Rats With Permanent Brain Ischemia. Frontiers in neuroscience 2018; 12:405. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970982
  20. Karimi B, Ashrafi M, Shomali T, Yektaseresht A. Therapeutic effect of simvastatin on DMBA-induced breast cancer in mice. Fundamental & clinical pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962034
  21. Tripathi DM, Vilaseca M, Lafoz E et al. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055171
  22. Ho YR, Lin CH, Kuo CY. The protective effect of simvastatin against ultraviolet B-induced corneal endothelial cell death. Indian journal of ophthalmology 2018; 66:1080-1083. http://www.ncbi.nlm.nih.gov/pubmed/?term=30038146
  23. Abd-Elsalam WH, El-Helaly SN, Ahmed MA, Al-Mahallawi AM. Preparation of novel phospholipid-based sonocomplexes for improved intestinal permeability of rosuvastatin: In vitro characterization, dynamic simulation, Caco-2 cell line permeation and in vivo assessment studies. Int J Pharm 2018; 548:375-384. http://www.ncbi.nlm.nih.gov/pubmed/?term=29991454
  24. Pohlen M, Pirker L, Lustrik M, Dreu R. A redispersible dry emulsion system with simvastatin prepared via fluid bed layering as a means of dissolution enhancement of a lipophilic drug. Int J Pharm 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075251
  25. Hamzeh M, Hosseinimehr SJ, Mohammadi HR et al. Atorvastatin attenuates the ovarian damage induced by cyclophosphamide in rat: An experimental study. International journal of reproductive biomedicine (Yazd, Iran) 2018; 16:323-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027148
  26. Yang MY, Diao ZY, Wang ZY et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing fetal development of rats. Journal of biomedical research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008464
  27. Yaghobee S, Ghahroudi A, Khorsand A et al. Radiographic Comparison of Bovine Bone Substitute Alone Versus Bovine Bone Substitute and Simvastatin for Human Maxillary Sinus Augmentation. Journal of dentistry (Tehran, Iran) 2018; 15:20-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971118
  28. Zhang X, Xiao S, Li Q. Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice. J Int Med Res 2018:300060518787671. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058421
  29. Turner RM, Fontana V, Bayliss M et al. Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. Journal of pharmaceutical and biomedical analysis 2018; 159:272-281. http://www.ncbi.nlm.nih.gov/pubmed/?term=30005242
  30. Choo EH, Han EJ, Kim CJ et al. Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT. Korean Circ J 2018; 48:591-601. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968431
  31. Wang L, Wang Y, Wang H et al. The influence of the intestinal microflora to the efficacy of Rosuvastatin. Lipids Health Dis 2018; 17:151. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960598
  32. Chen Z, Xiang Y, Bao B et al. Simvastatin improves cerebrovascular injury caused by ischemiareperfusion through NFkappaBmediated apoptosis via MyD88/TRIF signaling. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30066928
  33. Li H, Chen C, Wang D. Lowfrequency ultrasound and microbubbles combined with simvastatin promote the apoptosis of MCF7 cells by affecting the LATS1/YAP/RHAMM pathway. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015955
  34. Yu Q, Wang F, Meng X et al. Shortterm use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015940
  35. Choi NY, Kim JY, Hwang M et al. Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen-Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways. Mol Neurobiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073508
  36. Abdanipour A, Deheshjo F, Sohrabi D et al. Neuroprotective effect of lovastatin through down-regulation of pro-apoptotic Mst1 gene expression in rat model pilocarpine epilepsy. Neurol Res 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30048231
  37. Zhang H, Moriyama Y, Ayukawa Y et al. Generation and histomorphometric evaluation of a novel fluvastatin-containing poly(lactic-co-glycolic acid) membrane for guided bone regeneration. Odontology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30022371
  38. Ishikawa T, Hosaka YZ, Beckwitt C et al. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics. Oncotarget 2018; 9:29304-29315. http://www.ncbi.nlm.nih.gov/pubmed/?term=30034619
  39. Kamal S, Akhter N, Khan SG et al. Enhanced production of Lovastatin by filamentous fungi through solid state fermentation. Pak J Pharm Sci 2018; 31:1583-1589. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058552
  40. Moid M, Afzal S, Rahim N et al. High performance liquid chromatographic method validation for determination of rosuvastatin calcium in tablet dosage forms. Pak J Pharm Sci 2018; 31:1577-1582. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058551
  41. Alshora DH, Ibrahim MA, Elzayat E et al. Rosuvastatin calcium nanoparticles: Improving bioavailability by formulation and stabilization codesign. PLoS One 2018; 13:e0200218. http://www.ncbi.nlm.nih.gov/pubmed/?term=29985967
  42. Husain I, Akhtar M, Madaan T et al. Rosuvastatin alleviates high-salt and cholesterol diet-induced cognitive impairment in rats via Nrf2-ARE pathway. Redox report : communications in free radical research 2018; 23:168-179. http://www.ncbi.nlm.nih.gov/pubmed/?term=29961403
  43. Ma YR, Wu YF, Duan YQ et al. [Effects of metoprolol or/and pravastatin on the pharmacokinetics of metformin in rats]. Yao xue xue bao = Acta pharmaceutica Sinica 2017; 52:253-257. http://www.ncbi.nlm.nih.gov/pubmed/?term=29979507
  44. Chen B, Kang C, Yu D et al. [Different effects of simvastatin on keloid fibroblasts under hypoxia and TGF-beta1 treatment]. Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery 2016; 32:130-135. http://www.ncbi.nlm.nih.gov/pubmed/?term=30024693

Cancer

  1. Camacho L, Zabala-Letona A, Carracedo A. Re-evaluating statin activity in cancer. Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30036187
  2. Shih HJ, Tsai PS, Wen YC et al. Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement. The aging male : the official journal of the International Society for the Study of the Aging Male 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058422
  3. Arima R, Marttila M, Hautakoski A et al. Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes. Anticancer research 2018; 38:4169-4178. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970546
  4. Wang C, Li T, Yan F et al. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 105:1054-1061. http://www.ncbi.nlm.nih.gov/pubmed/?term=30021341
  5. Urpilainen E, Marttila M, Hautakoski A et al. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer 2018; 18:767. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055585
  6. Murtola TJ, Syvala H, Tolonen T et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. European urology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30031572
  7. Karimi B, Ashrafi M, Shomali T, Yektaseresht A. Therapeutic effect of simvastatin on DMBA-induced breast cancer in mice. Fundamental & clinical pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962034
  8. Potluri R, Carter PR, Lavu D, Bainey KR. The interplay between cholesterol and breast cancer: is there a potential role for statin therapy? Future oncology (London, England) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30051723
  9. Green DM, Wang M, Krasin MJ et al. Serum ALT elevations in survivors of childhood cancer. A report from the St. Jude Lifetime Cohort Study. Hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30016547
  10. Akinwunmi B, Vitonis AF, Titus L et al. Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006925
  11. Hamzeh M, Hosseinimehr SJ, Mohammadi HR et al. Atorvastatin attenuates the ovarian damage induced by cyclophosphamide in rat: An experimental study. International journal of reproductive biomedicine (Yazd, Iran) 2018; 16:323-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027148
  12. Ishikawa T, Hosaka YZ, Beckwitt C et al. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics. Oncotarget 2018; 9:29304-29315. http://www.ncbi.nlm.nih.gov/pubmed/?term=30034619

Children

  1. Kosmeri C, Siomou E, Vlahos AP, Milionis H. Review shows that lipid disorders are associated with endothelial but not renal dysfunction in children. Acta paediatrica (Oslo, Norway : 1992) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30066344
  2. Lyons SK, Boyle CT, DeSalvo DJ et al. Dyslipidemia and statin use in youth and adults ages 10-<40 years in the T1D Exchange Clinic Registry. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039636

Cost-effectiveness

  1. Kodera S, Morita H, Kiyosue A et al. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033948
  2. Leporowski A, Godman B, Kurdi A et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish National Health System: influence and implications. Expert review of pharmacoeconomics & outcomes research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30014725

CVD

  1. Rana JS, Liu JY, Moffet HH et al. Risk of Incident Atherosclerotic Cardiovascular Disease Events by Achieved Atherogenic Lipid Levels Among 62,428 Statin-Treated Individuals With Diabetes Mellitus. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30057224
  2. Kereiakes DJ, Lepor NE, Gerber R et al. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30025648
  3. Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55mg/dL. Atherosclerosis 2018; 275:262-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=29980053
  4. Liu ZJ, Hu GP, Fei MY et al. Effects of Short-term High Dose Atorvastatin on Left Ventricular Remodeling in Patients with First Time Attack of Anterior Acute Myocardial Infarction. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences 2018; 33:84-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29976277
  5. Marzal D, Rodriguez Padial L, Arnaiz JA et al. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention. Clin Investig Arterioscler 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30017176
  6. Lim JW, Jeong HS, Hong SJ et al. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30047013
  7. Nose D, Shiga Y, Ueda Y et al. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29974199
  8. Rymer JA, Newby LK. Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes. JACC. Basic to translational science 2017; 2:484-497. http://www.ncbi.nlm.nih.gov/pubmed/?term=30062164

Endothelium/inflammation

  1. Kosmeri C, Siomou E, Vlahos AP, Milionis H. Review shows that lipid disorders are associated with endothelial but not renal dysfunction in children. Acta paediatrica (Oslo, Norway : 1992) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30066344
  2. Ruscica M, Ferri N, Macchi C et al. Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes? Annals of medicine 2018:1-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=29976096
  3. Tissier F, Farhat F, Philouze C et al. Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in WHHL rabbit. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30011375
  4. Kim CJ, Han EJ, Chu EH et al. Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery. Cardiology journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30009378
  5. Psarros C, Economou EK, Koutsilieris M, Antoniades C. Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) 2015; 1:43-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=29967815
  6. Zhang X, Xiao S, Li Q. Pravastatin polarizes the phenotype of macrophages toward M2 and elevates serum cholesterol levels in apolipoprotein E knockout mice. J Int Med Res 2018:300060518787671. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058421
  7. Rymer JA, Newby LK. Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes. JACC. Basic to translational science 2017; 2:484-497. http://www.ncbi.nlm.nih.gov/pubmed/?term=30062164
  8. Lee JY, Cha BS. Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation. Korean Circ J 2018; 48:602-604. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968432
  9. Ye H, Wang S, Hu Y et al. Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography. Medicine (Baltimore) 2018; 97:e11718. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075578

Ethnicity

  1. Naumovska Z, Nestorovska AK, Grozdanova A et al. Evaluation of statin utilization in the Republic of Macedonia during 2013-2016. Clinicoecon Outcomes Res 2018; 10:339-347. http://www.ncbi.nlm.nih.gov/pubmed/?term=29983582
  2. Lim JW, Jeong HS, Hong SJ et al. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30047013
  3. Teramoto T, Usami M, Takagi Y, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30068817
  4. Lin SM, Wang JH, Liang CC, Huang HK. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29982482
  5. Al Sifri S, Al Shammeri O, Al Jaser S et al. Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. Saudi medical journal 2018; 39:697-704. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968891

FH

  1. De Luca L, Arca M, Temporelli PL et al. Prevalence and Pharmacologic Management of Familial Hypercholesterolemia in an Unselected Contemporary Cohort of Patients With Stable Coronary Artery Disease. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039543

Genetics

  1. Alzghari SK. An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity. Cureus 2018; 10:e2557. http://www.ncbi.nlm.nih.gov/pubmed/?term=29974012
  2. Roberts R, Campillo A. Genetic stratification for primary prevention of coronary artery disease. Current opinion in cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29979201
  3. Danielak D, Karazniewicz-Lada M, Glowka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30003466
  4. Einbond LS, Soffritti M, Esposti DD et al. A transcriptomic analysis of black cohosh: Actein alters cholesterol biosynthesis pathways and synergizes with simvastatin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29969672
  5. Ji T, Zhao Y, Wang J et al. Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial. Journal of the American Medical Directors Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006015
  6. Liu N, Yang G, Hu M et al. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30024814
  7. Enko D, Harringer S, Oberkanins C et al. SLCO1B1 c.521T>C Genotyping in the Austrian Population Using 2 Commercial Real-Time Polymerase Chain Reaction Assays: An Implementation Study. Pharmacology 2018; 102:88-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29969773

Guidelines

  1. Giral P. Comparison of Five Major Guidelines for Statin Use in Primary Prevention. Annals of internal medicine 2018; 169:67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971418
  2. Lindblad AJ, Korownyk C. Comparison of Five Major Guidelines for Statin Use in Primary Prevention. Annals of internal medicine 2018; 169:66-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971419
  3. Mortensen MB, Nordestgaard B. Comparison of Five Major Guidelines for Statin Use in Primary Prevention. Annals of internal medicine 2018; 169:67-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971420
  4. Harrison TN, Scott RD, Cheetham TC et al. Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30062465
  5. Ho K, Jamsen KM, Bell JS et al. Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027413
  6. Breuker C, Clement F, Mura T et al. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Int J Cardiol 2018; 268:195-199. http://www.ncbi.nlm.nih.gov/pubmed/?term=30041785
  7. Li YH, Yeh HI, Jeng JS, Charng MJ. Comparison of the 2017 Taiwan Lipid Guidelines and the Western Lipid Guidelines for High Risk Patients. Journal of the Chinese Medical Association : JCMA 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29980360
  8. Mora S, Wenger NK, Cook NR et al. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039172
  9. Galan I, Verdalles U, Garcia de Vinuesa M et al. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2018; 38:379-385. http://www.ncbi.nlm.nih.gov/pubmed/?term=30032855
  10. Al Sifri S, Al Shammeri O, Al Jaser S et al. Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. Saudi medical journal 2018; 39:697-704. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968891

LDL- related parameters

  1. Rana JS, Liu JY, Moffet HH et al. Risk of Incident Atherosclerotic Cardiovascular Disease Events by Achieved Atherogenic Lipid Levels Among 62,428 Statin-Treated Individuals With Diabetes Mellitus. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30057224
  2. Rodriguez F, Knowles JW, Maron DJ et al. Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol >/=190 mg/dl from the Veterans Affairs Health System. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055758
  3. Ruscica M, Ferri N, Macchi C et al. Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes? Annals of medicine 2018:1-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=29976096
  4. Baris G, Mach F. Lipid management in ACS: Should we go lower faster? Atherosclerosis 2018; 275:368-375. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015301
  5. Harrison TN, Scott RD, Cheetham TC et al. Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30062465
  6. Breuker C, Clement F, Mura T et al. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Int J Cardiol 2018; 268:195-199. http://www.ncbi.nlm.nih.gov/pubmed/?term=30041785
  7. Sabatine MS, Wiviott SD, Im K et al. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073316
  8. Jeyamalar R, Wan Azman WA, Nawawi H et al. Updates in the management of Dyslipidaemia in the high and very high risk individual for CV risk reduction. The Medical journal of Malaysia 2018; 73:154-162. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962499
  9. Al Sifri S, Al Shammeri O, Al Jaser S et al. Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. Saudi medical journal 2018; 39:697-704. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968891

Lifestyle

  1. Cofan M, Ros E. Use of plant sterol and stanol fortified foods in clinical practice. Curr Med Chem 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984649
  2. Dagenais GR, Jung H, Lonn E et al. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033433

Meta-analyses

  1. Ironside N, Brenner D, Heyer E et al. Systematic review and meta-analysis of perioperative and long-term outcomes in patients receiving statin therapy before carotid endarterectomy. Acta neurochirurgica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30019211
  2. Hackam DG, Vyas MV. Utilization of Vasculoprotective Therapy for Peripheral Artery Disease: A Systematic Review and Meta-analysis. Am J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30056102
  3. Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs in context 2018; 7:212534. http://www.ncbi.nlm.nih.gov/pubmed/?term=30023003
  4. Fan Y, Jin X, Man C, Gong D. Does Adjuvant Treatment With Ginkgo Biloba to Statins Have Additional Benefits in Patients With Dyslipidemia? Frontiers in pharmacology 2018; 9:659. http://www.ncbi.nlm.nih.gov/pubmed/?term=29988404
  5. Chen M, Ji M, Si X. The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials. Medicine (Baltimore) 2018; 97:e11578. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075526
  6. Safouris A, Katsanos AH, Kerasnoudis A et al. Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis: A Systematic Review and Meta-Analysis. Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29991656

Metabolic Syndrome - Diabetes

  1. Arima R, Marttila M, Hautakoski A et al. Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes. Anticancer research 2018; 38:4169-4178. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970546
  2. Urpilainen E, Marttila M, Hautakoski A et al. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer 2018; 18:767. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055585
  3. van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular diabetology 2018; 17:94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960584
  4. Lyons SK, Boyle CT, DeSalvo DJ et al. Dyslipidemia and statin use in youth and adults ages 10-<40 years in the T1D Exchange Clinic Registry. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039636
  5. Ho K, Jamsen KM, Bell JS et al. Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027413
  6. Janssen VE, Visseren FL, de Boer A et al. Combined use of polypill components in patients with type 2 diabetes mellitus. Eur J Prev Cardiol 2018:2047487318789494. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033753
  7. Bagheri B, Alikhani A, Mokhtari H, Rasouli M. Esterification of HDL-cholesterol is Decreased in Diabetes Mellitus and CAD and Enhanced Following Treatment with Statins. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:197-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=30061766
  8. Yu Q, Wang F, Meng X et al. Shortterm use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015940  

New Treatments

  1. Chandra Ghosh G, Bandyopadhyay D, Ghosh RK et al. Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075894
  2. Baris G, Mach F. Lipid management in ACS: Should we go lower faster? Atherosclerosis 2018; 275:368-375. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015301
  3. Kereiakes DJ, Lepor NE, Gerber R et al. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30025648
  4. Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55mg/dL. Atherosclerosis 2018; 275:262-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=29980053
  5. Cho L, Dent R, Stroes ESG et al. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073585
  6. Kodera S, Morita H, Kiyosue A et al. Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033948
  7. Lorenzatti AJ, Eliaschewitz FG, Chen Y et al. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: the BERSON clinical trial. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962050
  8. Kosmas CE, Munoz Estrella A, Sourlas A et al. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Diseases (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30011788
  9. Kroger K, Espinola-Klein C, Hoffmann U et al. [Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]. Deutsche medizinische Wochenschrift (1946) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29972852
  10. Singh A, Davidson M. Update on PCSK9 therapies for the treatment of dyslipidemia. Expert review of endocrinology & metabolism 2016; 11:87-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=30063452
  11. Shahreyar M, Salem SA, Nayyar M et al. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. Journal of the American Board of Family Medicine : JABFM 2018; 31:628-634. http://www.ncbi.nlm.nih.gov/pubmed/?term=29986989
  12. Teramoto T, Usami M, Takagi Y, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30068817

Other

  1. Nikolic Turnic TR, Jakovljevic VP, Djuric D et al. EFFICENCY OF ATORVASTATIN AND SIMVASTATIN IN IMPROVING OF CARDIAC FUNCTION DURING THE DIFFERENT DEGREE OF HYPERHOMOCYSTEINEMIA. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30067069
  2. Kerut EK, Hall ME, Turner MC, McMullan MR. Coronary risk assessment using traditional risk factors with CT coronary artery calcium scoring in clinical practice. Echocardiography (Mount Kisco, N.Y.) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29974506
  3. Leporowski A, Godman B, Kurdi A et al. Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish National Health System: influence and implications. Expert review of pharmacoeconomics & outcomes research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30014725
  4. Drake ES, Harris DK, Marciniak MW. Community pharmacist-led intervention to identify persons with diabetes not on statin therapy. Journal of the American Pharmacists Association : JAPhA 2018; 58:S125-s130. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006183
  5. Wang L, Wang Y, Wang H et al. The influence of the intestinal microflora to the efficacy of Rosuvastatin. Lipids Health Dis 2018; 17:151. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960598

PAD and statins

  1. Hackam DG, Vyas MV. Utilization of Vasculoprotective Therapy for Peripheral Artery Disease: A Systematic Review and Meta-analysis. Am J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30056102
  2. Kroger K, Espinola-Klein C, Hoffmann U et al. [Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]. Deutsche medizinische Wochenschrift (1946) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29972852

Pleiotropic effects of statins

  1. Huang J, Lin C, Fang J et al. The pH-sensitive nanocarrier mediated codelivery of simvastatin and noggin siRNA for synergistic enhancement of osteogenesis. ACS applied materials & interfaces 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30067011
  2. Li J, Feng X, Shi J et al. Porous Polylactide Film Plus Atorvastatin-Loaded Thermogel as an Efficient Device for Peritoneal Adhesion Prevention. ACS omega 2018; 3:2715-2723. http://www.ncbi.nlm.nih.gov/pubmed/?term=30023849
  3. Sayeed S, Hernandez AF. Review: In noncardiac surgery, amiodarone, beta-blocker, or statin prophylaxis reduces postoperative AF. Annals of internal medicine 2018; 169:Jc7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30014096
  4. Arima R, Marttila M, Hautakoski A et al. Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes. Anticancer research 2018; 38:4169-4178. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970546
  5. Araujo-Lima CF, Peres RB, Silva PB et al. Repurposing strategy of atorvastatin against Trypanosoma cruzi: in vitro monotherapy and combined therapy with benznidazole exhibits synergistic trypanocidal activity. Antimicrobial agents and chemotherapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29987140
  6. Tokuhisa H, Murai H, Okabe Y et al. Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction. Autonomic neuroscience : basic & clinical 2018; 213:8-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30005743
  7. Wang C, Li T, Yan F et al. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 105:1054-1061. http://www.ncbi.nlm.nih.gov/pubmed/?term=30021341
  8. Ozkan B, Orscelik O, Uyar H et al. Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease. BioMed research international 2018; 2018:8961690. http://www.ncbi.nlm.nih.gov/pubmed/?term=29977920
  9. Zhou J, Gao X, Huang S et al. Simvastatin Improves the Jaw Bone Microstructural Defect Induced by High Cholesterol Diet in Rats by Regulating Autophagic Flux. BioMed research international 2018; 2018:4147932. http://www.ncbi.nlm.nih.gov/pubmed/?term=30050930
  10. van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular diabetology 2018; 17:94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960584
  11. Sigler MA, Congdon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clinical medicine insights. Gastroenterology 2018; 11:1179552218787502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30013416
  12. Ren J, Liu W, Li GC et al. Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCepsilon Pathway. Current medical science 2018; 38:405-412. http://www.ncbi.nlm.nih.gov/pubmed/?term=30074205
  13. Mohammad S, Nguyen H, Nguyen M et al. Pleotropic Effects of Statins: untapped potential for statin pharmacotherapy. Current vascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033872
  14. Dworacka M, Iskakova S, Wesolowska A et al. Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability. Diabetes Res Clin Pract 2018; 143:245-253. http://www.ncbi.nlm.nih.gov/pubmed/?term=30056191
  15. Xie Y, Liu C, Huang H et al. Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment. Drug delivery and translational research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027372
  16. Ruan H, Yu Y, Guo X et al. The possibility of healing alveolar bone defects with simvastatin thermosensitive gel: in vitro/in vivo evaluation. Drug design, development and therapy 2018; 12:1997-2003. http://www.ncbi.nlm.nih.gov/pubmed/?term=30013319
  17. Asleh R, Briasoulis A, Pereira NL et al. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC heart failure 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30019530
  18. Wang HM, Gao JH, Lu JL. Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12. Eur Rev Med Pharmacol Sci 2018; 22:4995-5003. http://www.ncbi.nlm.nih.gov/pubmed/?term=30070336
  19. Tripathi DM, Vilaseca M, Lafoz E et al. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055171
  20. Seyam E, Hefzy E. Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30044162
  21. Ho YR, Lin CH, Kuo CY. The protective effect of simvastatin against ultraviolet B-induced corneal endothelial cell death. Indian journal of ophthalmology 2018; 66:1080-1083. http://www.ncbi.nlm.nih.gov/pubmed/?term=30038146
  22. Hamzeh M, Hosseinimehr SJ, Mohammadi HR et al. Atorvastatin attenuates the ovarian damage induced by cyclophosphamide in rat: An experimental study. International journal of reproductive biomedicine (Yazd, Iran) 2018; 16:323-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027148
  23. Reynolds AL, Del Monte MA, Archer SM. The effect of oral statin therapy on strabismus in patients with thyroid eye disease. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075294
  24. Yang MY, Diao ZY, Wang ZY et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing fetal development of rats. Journal of biomedical research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008464
  25. Zhou L, Liu X, Wang ZQ et al. Simvastatin Treatment Protects Myocardium in Non-coronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting. Journal of cardiovascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29985281
  26. Lin SM, Wang JH, Liang CC, Huang HK. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29982482
  27. Psarros C, Economou EK, Koutsilieris M, Antoniades C. Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) 2015; 1:43-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=29967815
  28. Yaghobee S, Ghahroudi A, Khorsand A et al. Radiographic Comparison of Bovine Bone Substitute Alone Versus Bovine Bone Substitute and Simvastatin for Human Maxillary Sinus Augmentation. Journal of dentistry (Tehran, Iran) 2018; 15:20-29. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971118
  29. Pose E, Trebicka J, Mookerjee RP et al. Statins: old drugs as new therapy for liver diseases? J Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075229
  30. Cheung KL, Zakai NA, Callas PW et al. Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS Study. Journal of thrombosis and haemostasis : JTH 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984467
  31. Choo EH, Han EJ, Kim CJ et al. Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT. Korean Circ J 2018; 48:591-601. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968431
  32. Akbari H, Asadikaram G, Jafari A et al. Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29981321
  33. Rakhmatia YD, Ayukawa Y, Furuhashi A, Koyano K. Carbonate Apatite Containing Statin Enhances Bone Formation in Healing Incisal Extraction Sockets in Rats. Materials (Basel, Switzerland) 2018; 11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30002343
  34. Bagheri B, Alikhani A, Mokhtari H, Rasouli M. Esterification of HDL-cholesterol is Decreased in Diabetes Mellitus and CAD and Enhanced Following Treatment with Statins. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:197-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=30061766
  35. Chen M, Ji M, Si X. The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials. Medicine (Baltimore) 2018; 97:e11578. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075526
  36. Zhang X, Wen J, Zhang Z. Statins use and risk of dementia: A dose-response meta analysis. Medicine (Baltimore) 2018; 97:e11304. http://www.ncbi.nlm.nih.gov/pubmed/?term=30045255
  37. Chen Z, Xiang Y, Bao B et al. Simvastatin improves cerebrovascular injury caused by ischemiareperfusion through NFkappaBmediated apoptosis via MyD88/TRIF signaling. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30066928
  38. Choi NY, Kim JY, Hwang M et al. Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen-Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways. Mol Neurobiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073508
  39. Abdanipour A, Deheshjo F, Sohrabi D et al. Neuroprotective effect of lovastatin through down-regulation of pro-apoptotic Mst1 gene expression in rat model pilocarpine epilepsy. Neurol Res 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30048231
  40. Saliba W, Rennert HS, Barnett-Griness O et al. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970405
  41. Zhang H, Moriyama Y, Ayukawa Y et al. Generation and histomorphometric evaluation of a novel fluvastatin-containing poly(lactic-co-glycolic acid) membrane for guided bone regeneration. Odontology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30022371
  42. Wybraniec MT, Filipecki A, Chudek J, Mizia-Stec K. Atorvastatin facilitates protection against contrast-induced nephropathy in patients undergoing coronary angiography via humoral mediators rather than altered renal hemodynamics. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology 2018; 14:191-194. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008773
  43. Braekkan SK, Caram-Deelder C, Siegerink B et al. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Research and practice in thrombosis and haemostasis 2017; 1:112-119. http://www.ncbi.nlm.nih.gov/pubmed/?term=30046679

Primary Prevention

  1. Roberts R, Campillo A. Genetic stratification for primary prevention of coronary artery disease. Current opinion in cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29979201
  2. Kaltoft MK, Nielsen JB, Dowie J. Risk Thresholds and Risk Classifications Pose Problems for Person-Centred Care. Studies in health technology and informatics 2018; 251:19-22. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968591

Registry data

  1. Shih HJ, Tsai PS, Wen YC et al. Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement. The aging male : the official journal of the International Society for the Study of the Aging Male 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058422
  2. Rana JS, Liu JY, Moffet HH et al. Risk of Incident Atherosclerotic Cardiovascular Disease Events by Achieved Atherogenic Lipid Levels Among 62,428 Statin-Treated Individuals With Diabetes Mellitus. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30057224
  3. Rodriguez F, Knowles JW, Maron DJ et al. Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol >/=190 mg/dl from the Veterans Affairs Health System. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055758
  4. Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55mg/dL. Atherosclerosis 2018; 275:262-264. http://www.ncbi.nlm.nih.gov/pubmed/?term=29980053
  5. Urpilainen E, Marttila M, Hautakoski A et al. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer 2018; 18:767. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055585
  6. Harrison TN, Scott RD, Cheetham TC et al. Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30062465
  7. Naumovska Z, Nestorovska AK, Grozdanova A et al. Evaluation of statin utilization in the Republic of Macedonia during 2013-2016. Clinicoecon Outcomes Res 2018; 10:339-347. http://www.ncbi.nlm.nih.gov/pubmed/?term=29983582
  8. Lyons SK, Boyle CT, DeSalvo DJ et al. Dyslipidemia and statin use in youth and adults ages 10-<40 years in the T1D Exchange Clinic Registry. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039636
  9. Lind PM, Salihovic S, Stubleski J et al. Changes in plasma levels of perfluoroalkyl substances (PFASs) are related to increase in carotid intima-media thickness over 10 years - a longitudinal study. Environmental health : a global access science source 2018; 17:59. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970113
  10. Asleh R, Briasoulis A, Pereira NL et al. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients. ESC heart failure 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30019530
  11. Ho K, Jamsen KM, Bell JS et al. Demographic, clinical and lifestyle factors associated with high-intensity statin therapy in Australia: the AusDiab study. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30027413
  12. Murtola TJ, Syvala H, Tolonen T et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. European urology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30031572
  13. Green DM, Wang M, Krasin MJ et al. Serum ALT elevations in survivors of childhood cancer. A report from the St. Jude Lifetime Cohort Study. Hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30016547
  14. Akinwunmi B, Vitonis AF, Titus L et al. Statin Therapy and Association with Ovarian Cancer risk in the New England Case Control (NEC) Study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006925
  15. Breuker C, Clement F, Mura T et al. Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: Incidence and risk factors. Int J Cardiol 2018; 268:195-199. http://www.ncbi.nlm.nih.gov/pubmed/?term=30041785
  16. Rej S, Schulte SW, Rajji TK et al. Statins and cognition in late-life bipolar disorder. International journal of geriatric psychiatry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30022520
  17. Yamamoto H, Kihara Y, Kitagawa T et al. Coronary plaque characteristics in computed tomography and 2-year outcomes: The PREDICT study. Journal of cardiovascular computed tomography 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30017608
  18. Lin SM, Wang JH, Liang CC, Huang HK. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29982482
  19. Cheung KL, Zakai NA, Callas PW et al. Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS Study. Journal of thrombosis and haemostasis : JTH 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984467
  20. Caughey GE, Gabb GM, Ronson S et al. Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073275
  21. Mora S, Wenger NK, Cook NR et al. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30039172
  22. Bagheri B, Alikhani A, Mokhtari H, Rasouli M. Esterification of HDL-cholesterol is Decreased in Diabetes Mellitus and CAD and Enhanced Following Treatment with Statins. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:197-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=30061766
  23. Chen M, Ji M, Si X. The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials. Medicine (Baltimore) 2018; 97:e11578. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075526
  24. Zhang X, Wen J, Zhang Z. Statins use and risk of dementia: A dose-response meta analysis. Medicine (Baltimore) 2018; 97:e11304. http://www.ncbi.nlm.nih.gov/pubmed/?term=30045255
  25. Walther CP, Richardson PA, Virani SS et al. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30053252
  26. Saliba W, Rennert HS, Barnett-Griness O et al. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970405
  27. Liu N, Yang G, Hu M et al. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30024814

Renal Disease

  1. Fukumoto Y. Impact of statin-ezetimibe combination in chronic kidney disease. Int J Cardiol 2018; 268:36-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30041796
  2. Walther CP, Richardson PA, Virani SS et al. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30053252
  3. Wybraniec MT, Filipecki A, Chudek J, Mizia-Stec K. Atorvastatin facilitates protection against contrast-induced nephropathy in patients undergoing coronary angiography via humoral mediators rather than altered renal hemodynamics. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology 2018; 14:191-194. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008773

Reviews

  1. Kosmeri C, Siomou E, Vlahos AP, Milionis H. Review shows that lipid disorders are associated with endothelial but not renal dysfunction in children. Acta paediatrica (Oslo, Norway : 1992) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30066344
  2. Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but. Advances in nutrition (Bethesda, Md.) 2018; 9:519s-523s. http://www.ncbi.nlm.nih.gov/pubmed/?term=30032220
  3. Camacho L, Zabala-Letona A, Carracedo A. Re-evaluating statin activity in cancer. Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30036187
  4. Chandra Ghosh G, Bandyopadhyay D, Ghosh RK et al. Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075894
  5. Giral P. Comparison of Five Major Guidelines for Statin Use in Primary Prevention. Annals of internal medicine 2018; 169:67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971418
  6. Lindblad AJ, Korownyk C. Comparison of Five Major Guidelines for Statin Use in Primary Prevention. Annals of internal medicine 2018; 169:66-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971419
  7. Mortensen MB, Nordestgaard B. Comparison of Five Major Guidelines for Statin Use in Primary Prevention. Annals of internal medicine 2018; 169:67-68. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971420
  8. Sayeed S, Hernandez AF. Review: In noncardiac surgery, amiodarone, beta-blocker, or statin prophylaxis reduces postoperative AF. Annals of internal medicine 2018; 169:Jc7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30014096
  9. Ruscica M, Ferri N, Macchi C et al. Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes? Annals of medicine 2018:1-46. http://www.ncbi.nlm.nih.gov/pubmed/?term=29976096
  10. Baris G, Mach F. Lipid management in ACS: Should we go lower faster? Atherosclerosis 2018; 275:368-375. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015301
  11. Bobrovitz N, Heneghan C, Onakpoya I et al. Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments. BMC Med 2018; 16:115. http://www.ncbi.nlm.nih.gov/pubmed/?term=30045724
  12. van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovascular diabetology 2018; 17:94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29960584
  13. Sigler MA, Congdon L, Edwards KL. An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. Clinical medicine insights. Gastroenterology 2018; 11:1179552218787502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30013416
  14. Alzghari SK. An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity. Cureus 2018; 10:e2557. http://www.ncbi.nlm.nih.gov/pubmed/?term=29974012
  15. Cofan M, Ros E. Use of plant sterol and stanol fortified foods in clinical practice. Curr Med Chem 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984649
  16. Roberts R, Campillo A. Genetic stratification for primary prevention of coronary artery disease. Current opinion in cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29979201
  17. Wei J, Shufelt C, Bairey Merz CN. Women's health: making cardiovascular disease real. Current opinion in cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29985202
  18. Mohammad S, Nguyen H, Nguyen M et al. Pleotropic Effects of Statins: untapped potential for statin pharmacotherapy. Current vascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033872
  19. Ricci G, Ciccone MM, Giordano P, Cortese F. Statins: pharmacokinetics, pharmacodynamics, and cost-effectiveness analysis. Current vascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984667
  20. Kosmas CE, Munoz Estrella A, Sourlas A et al. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Diseases (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30011788
  21. Bougarne N, Weyers B, Desmet SJ et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocrine reviews 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30020428
  22. Singh A, Davidson M. Update on PCSK9 therapies for the treatment of dyslipidemia. Expert review of endocrinology & metabolism 2016; 11:87-95. http://www.ncbi.nlm.nih.gov/pubmed/?term=30063452
  23. Potluri R, Carter PR, Lavu D, Bainey KR. The interplay between cholesterol and breast cancer: is there a potential role for statin therapy? Future oncology (London, England) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30051723
  24. Karsanidze A, Antelava N, Gorgasledze N et al. STATIN-ASSOCIATED INTOLERANCE AND ITS PREVENTION. Georgian medical news 2018:155-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30035739
  25. Ibanez B, Castellano JM, Fuster V. Polypill strategy at the heart of cardiovascular secondary prevention. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30030331
  26. Shahreyar M, Salem SA, Nayyar M et al. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. Journal of the American Board of Family Medicine : JABFM 2018; 31:628-634. http://www.ncbi.nlm.nih.gov/pubmed/?term=29986989
  27. Li YH, Yeh HI, Jeng JS, Charng MJ. Comparison of the 2017 Taiwan Lipid Guidelines and the Western Lipid Guidelines for High Risk Patients. Journal of the Chinese Medical Association : JCMA 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29980360
  28. Psarros C, Economou EK, Koutsilieris M, Antoniades C. Statins as Pleiotropic Modifiers of Vascular Oxidative Stress and Inflammation. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) 2015; 1:43-54. http://www.ncbi.nlm.nih.gov/pubmed/?term=29967815
  29. Pose E, Trebicka J, Mookerjee RP et al. Statins: old drugs as new therapy for liver diseases? J Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075229
  30. Rymer JA, Newby LK. Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes. JACC. Basic to translational science 2017; 2:484-497. http://www.ncbi.nlm.nih.gov/pubmed/?term=30062164
  31. Sabatine MS, Wiviott SD, Im K et al. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073316
  32. Curfman G. Statin-Associated Myopathy-An Elusive Clinical Problem. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073289
  33. Cybulska B, Klosiewicz-Latoszek L. How do we know that statins are diabetogenic and why? Is it an important issue in the clinical practice? Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30067279
  34. Jeyamalar R, Wan Azman WA, Nawawi H et al. Updates in the management of Dyslipidaemia in the high and very high risk individual for CV risk reduction. The Medical journal of Malaysia 2018; 73:154-162. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962499
  35. Galan I, Verdalles U, Garcia de Vinuesa M et al. Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2018; 38:379-385. http://www.ncbi.nlm.nih.gov/pubmed/?term=30032855
  36. Badescu C, Rezus E, Badescu L et al. New Drugs for Lowering LDL-Cholesterol. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2016; 120:485-490. http://www.ncbi.nlm.nih.gov/pubmed/?term=30044561

Safety and side effects

  1. Balke M, Brunn A, Claeys KG et al. Late onset necrotizing autoimmune myopathy 1 year after cessation of statin treatment. Acta neurologica Belgica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008064
  2. Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but. Advances in nutrition (Bethesda, Md.) 2018; 9:519s-523s. http://www.ncbi.nlm.nih.gov/pubmed/?term=30032220
  3. Mefford MT, Tajeu GS, Tanner RM et al. Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30057227
  4. Dougherty JA. Atorvastatin-Associated Macroglossia in a Cardioembolic Stroke Patient. The Annals of pharmacotherapy 2018:1060028018793111. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058342
  5. von Buedingen F, Hammer MS, Meid AD et al. Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. BMC family practice 2018; 19:131. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055583
  6. Cho L, Dent R, Stroes ESG et al. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073585
  7. Dixit A, Abrudescu A. A Case of Atorvastatin-Associated Necrotizing Autoimmune Myopathy, Mimicking Idiopathic Polymyositis. Case Rep Rheumatol 2018; 2018:5931046. http://www.ncbi.nlm.nih.gov/pubmed/?term=30026996
  8. Alzghari SK. An Unnecessary Pain: Using Pharmacogenetics for Statin-related Skeletal Muscle Toxicity. Cureus 2018; 10:e2557. http://www.ncbi.nlm.nih.gov/pubmed/?term=29974012
  9. Danielak D, Karazniewicz-Lada M, Glowka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30003466
  10. Marques AC, Busanello ENB, de Oliveira DN et al. Coenzyme Q10 or Creatine Counteract Pravastatin-Induced Liver Redox Changes in Hypercholesterolemic Mice. Frontiers in pharmacology 2018; 9:685. http://www.ncbi.nlm.nih.gov/pubmed/?term=29997512
  11. Karsanidze A, Antelava N, Gorgasledze N et al. Statin-Associated Intolerance and its Prevention. Georgian medical news 2018:155-161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30035739
  12. Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of medication errors. Heart 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30072364
  13. Green DM, Wang M, Krasin MJ et al. Serum ALT elevations in survivors of childhood cancer. A report from the St. Jude Lifetime Cohort Study. Hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30016547
  14. Lee MS, Hekimian A, Doctorian T, Duan L. Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29996977
  15. Rej S, Schulte SW, Rajji TK et al. Statins and cognition in late-life bipolar disorder. International journal of geriatric psychiatry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30022520
  16. Teramoto T, Usami M, Takagi Y, Baccara-Dinet MT. Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30068817
  17. Vithayathil M, Phung A. Near-Fatal Statin-Associated Autoimmune Myositis. Journal of clinical neurology (Seoul, Korea) 2018; 14:426-427. http://www.ncbi.nlm.nih.gov/pubmed/?term=29971985
  18. Sabatine MS, Wiviott SD, Im K et al. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073316
  19. Caughey GE, Gabb GM, Ronson S et al. Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073275
  20. Curfman G. Statin-Associated Myopathy-An Elusive Clinical Problem. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073289
  21. Jiang R, Zhao S, Wang R et al. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073290
  22. Cybulska B, Klosiewicz-Latoszek L. How do we know that statins are diabetogenic and why? Is it an important issue in the clinical practice? Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30067279
  23. Yu Q, Wang F, Meng X et al. Shortterm use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30015940
  24. Enko D, Harringer S, Oberkanins C et al. SLCO1B1 c.521T>C Genotyping in the Austrian Population Using 2 Commercial Real-Time Polymerase Chain Reaction Assays: An Implementation Study. Pharmacology 2018; 102:88-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29969773
  25. Ma YR, Wu YF, Duan YQ et al. [Effects of metoprolol or/and pravastatin on the pharmacokinetics of metformin in rats]. Yao xue xue bao = Acta pharmaceutica Sinica 2017; 52:253-257. http://www.ncbi.nlm.nih.gov/pubmed/?term=29979507

Stroke and CNS

  1. Ironside N, Brenner D, Heyer E et al. Systematic review and meta-analysis of perioperative and long-term outcomes in patients receiving statin therapy before carotid endarterectomy. Acta neurochirurgica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30019211
  2. Dougherty JA. Atorvastatin-Associated Macroglossia in a Cardioembolic Stroke Patient. The Annals of pharmacotherapy 2018:1060028018793111. http://www.ncbi.nlm.nih.gov/pubmed/?term=30058342
  3. Zhang T, Lu D, Yang W et al. HMG-CoA Reductase Inhibitors Relieve Endoplasmic Reticulum Stress by Autophagy Inhibition in Rats With Permanent Brain Ischemia. Frontiers in neuroscience 2018; 12:405. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970982
  4. Rej S, Schulte SW, Rajji TK et al. Statins and cognition in late-life bipolar disorder. International journal of geriatric psychiatry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30022520
  5. Ji T, Zhao Y, Wang J et al. Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial. Journal of the American Medical Directors Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006015
  6. Lin SM, Wang JH, Liang CC, Huang HK. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29982482
  7. Cheung KL, Zakai NA, Callas PW et al. Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS Study. Journal of thrombosis and haemostasis : JTH 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29984467
  8. Jiang R, Zhao S, Wang R et al. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073290
  9. Zhang X, Wen J, Zhang Z. Statins use and risk of dementia: A dose-response meta analysis. Medicine (Baltimore) 2018; 97:e11304. http://www.ncbi.nlm.nih.gov/pubmed/?term=30045255
  10. Saliba W, Rennert HS, Barnett-Griness O et al. Association of statin use with spontaneous intracerebral hemorrhage: A cohort study. Neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29970405
  11. Zhang J, Liu N, Yang C. Effects of Rosuvastatin in combination with Nimodipine in patients with mild cognitive impairment caused by CSVD. Panminerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962180
  12. Husain I, Akhtar M, Madaan T et al. Rosuvastatin alleviates high-salt and cholesterol diet-induced cognitive impairment in rats via Nrf2-ARE pathway. Redox report : communications in free radical research 2018; 23:168-179. http://www.ncbi.nlm.nih.gov/pubmed/?term=29961403
  13. Safouris A, Katsanos AH, Kerasnoudis A et al. Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis: A Systematic Review and Meta-Analysis. Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29991656

Triglycerides/HDL

  1. Bagheri B, Alikhani A, Mokhtari H, Rasouli M. Esterification of HDL-cholesterol is Decreased in Diabetes Mellitus and CAD and Enhanced Following Treatment with Statins. Medical archives (Sarajevo, Bosnia and Herzegovina) 2018; 72:197-201. http://www.ncbi.nlm.nih.gov/pubmed/?term=30061766
  2. Jeyamalar R, Wan Azman WA, Nawawi H et al. Updates in the management of Dyslipidaemia in the high and very high risk individual for CV risk reduction. The Medical journal of Malaysia 2018; 73:154-162. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962499
  3. Liu N, Yang G, Hu M et al. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30024814
  4. Ozaki Y, Tanaka A, Nishiguchi T et al. High-density lipoprotein cholesterol as a therapeutic target for residual risk in patients with acute coronary syndrome. PLoS One 2018; 13:e0200383. http://www.ncbi.nlm.nih.gov/pubmed/?term=29995934

Trials

  1. Kereiakes DJ, Lepor NE, Gerber R et al. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30025648
  2. Tokuhisa H, Murai H, Okabe Y et al. Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction. Autonomic neuroscience : basic & clinical 2018; 213:8-14. http://www.ncbi.nlm.nih.gov/pubmed/?term=30005743
  3. Ozkan B, Orscelik O, Uyar H et al. Awareness of Pleiotropic and Cardioprotective Effect of Statins in Patients with Coronary Artery Disease. BioMed research international 2018; 2018:8961690. http://www.ncbi.nlm.nih.gov/pubmed/?term=29977920
  4. Kim CJ, Han EJ, Chu EH et al. Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery. Cardiology journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30009378
  5. Cho L, Dent R, Stroes ESG et al. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30073585
  6. Liu ZJ, Hu GP, Fei MY et al. Effects of Short-term High Dose Atorvastatin on Left Ventricular Remodeling in Patients with First Time Attack of Anterior Acute Myocardial Infarction. Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih / Chinese Academy of Medical Sciences 2018; 33:84-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29976277
  7. Lorenzatti AJ, Eliaschewitz FG, Chen Y et al. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: the BERSON clinical trial. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962050
  8. Kroger K, Espinola-Klein C, Hoffmann U et al. [Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]. Deutsche medizinische Wochenschrift (1946) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29972852
  9. Seyam E, Hefzy E. Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30044162
  10. Lim JW, Jeong HS, Hong SJ et al. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis. Heart Vessels 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30047013
  11. Dagenais GR, Jung H, Lonn E et al. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30033433
  12. Ji T, Zhao Y, Wang J et al. Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial. Journal of the American Medical Directors Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006015
  13. Drake ES, Harris DK, Marciniak MW. Community pharmacist-led intervention to identify persons with diabetes not on statin therapy. Journal of the American Pharmacists Association : JAPhA 2018; 58:S125-s130. http://www.ncbi.nlm.nih.gov/pubmed/?term=30006183
  14. Zhou L, Liu X, Wang ZQ et al. Simvastatin Treatment Protects Myocardium in Non-coronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting. Journal of cardiovascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29985281
  15. Lee JY, Cha BS. Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation. Korean Circ J 2018; 48:602-604. http://www.ncbi.nlm.nih.gov/pubmed/?term=29968432
  16. Akbari H, Asadikaram G, Jafari A et al. Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29981321
  17. Ye H, Wang S, Hu Y et al. Therapeutic effects of different Atorvastatin doses on vulnerable plaques in coronary arteries assessed by intracoronary optical coherence tomography. Medicine (Baltimore) 2018; 97:e11718. http://www.ncbi.nlm.nih.gov/pubmed/?term=30075578
  18. Zhang J, Liu N, Yang C. Effects of Rosuvastatin in combination with Nimodipine in patients with mild cognitive impairment caused by CSVD. Panminerva medica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29962180
  19. Enko D, Harringer S, Oberkanins C et al. SLCO1B1 c.521T>C Genotyping in the Austrian Population Using 2 Commercial Real-Time Polymerase Chain Reaction Assays: An Implementation Study. Pharmacology 2018; 102:88-90. http://www.ncbi.nlm.nih.gov/pubmed/?term=29969773
  20. Ozaki Y, Tanaka A, Nishiguchi T et al. High-density lipoprotein cholesterol as a therapeutic target for residual risk in patients with acute coronary syndrome. PLoS One 2018; 13:e0200383. http://www.ncbi.nlm.nih.gov/pubmed/?term=29995934
  21. Braekkan SK, Caram-Deelder C, Siegerink B et al. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Research and practice in thrombosis and haemostasis 2017; 1:112-119. http://www.ncbi.nlm.nih.gov/pubmed/?term=30046679

Women and elderly

  1. Ofori-Asenso R, Ilomaki J, Tacey M et al. Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. American journal of Alzheimer's disease and other dementias 2018:1533317518787314. http://www.ncbi.nlm.nih.gov/pubmed/?term=29991271
  2. von Buedingen F, Hammer MS, Meid AD et al. Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. BMC family practice 2018; 19:131. http://www.ncbi.nlm.nih.gov/pubmed/?term=30055583
  3. Wei J, Shufelt C, Bairey Merz CN. Women's health: making cardiovascular disease real. Current opinion in cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29985202
  4. Thompson W, Pottegard A, Nielsen JB et al. How Common is Statin Use in the Oldest Old? Drugs Aging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29987758
  5. Ezetimibe. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  6. Rosuvastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  7. Atorvastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  8. Simvastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  9. Fluvastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  10. Lovastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  11. Pravastatin. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
  12. Seyam E, Hefzy E. Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=30044162
  13. Lee MS, Hekimian A, Doctorian T, Duan L. Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29996977
  14. Yang MY, Diao ZY, Wang ZY et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing fetal development of rats. Journal of biomedical research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30008464
 
 
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.